Tuesday, March 20, 2012 3:29:57 PM
MSHL ~ Key Developments, Chart & DD :
MSHL initiated with a Buy at Roth Capital : Target $2.25
Marshall Edwards submits investigational NDA for ME-344
Marshall Edwards announced that it has submitted an Investigational New Drug application to the FDA to initiate clinical testing for oncology drug candidate ME-344, the company's mitochondrial inhibitor. Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The company expects to collect final safety and pharmacokinetic data from this trial by June.
9:03AM Marshall Edwards announced that it has set the record date and pricing terms for its previously announced rights offering to existing stockholders (MSHL) 0.68 : For every two Units purchased in the rights offering, stockholders will receive one share of common stock at a price of $0.89 per share, which represents a 10 percent discount to the volume-weighted average price of the Company's common stock for the 30 consecutive trading days ending on, and inclusive of, March 13, 2012, and warrants to purchase one-half of a share of common stock at an exercise price of $1.19 per share, which represents a 20 percent premium to the volume-weighted average price of the Company's common stock during the same period.
http://finance.yahoo.com/marketupdate/inplay#mshl
DEVELOPMENTS:
CHART:
MSHL initiated with a Buy at Roth Capital : Target $2.25
Marshall Edwards submits investigational NDA for ME-344
Marshall Edwards announced that it has submitted an Investigational New Drug application to the FDA to initiate clinical testing for oncology drug candidate ME-344, the company's mitochondrial inhibitor. Marshall Edwards also announced that it has commenced dosing of the fourth cohort in its Phase I clinical trial of intravenous ME-143 in patients with solid refractory tumors. The company expects to collect final safety and pharmacokinetic data from this trial by June.
9:03AM Marshall Edwards announced that it has set the record date and pricing terms for its previously announced rights offering to existing stockholders (MSHL) 0.68 : For every two Units purchased in the rights offering, stockholders will receive one share of common stock at a price of $0.89 per share, which represents a 10 percent discount to the volume-weighted average price of the Company's common stock for the 30 consecutive trading days ending on, and inclusive of, March 13, 2012, and warrants to purchase one-half of a share of common stock at an exercise price of $1.19 per share, which represents a 20 percent premium to the volume-weighted average price of the Company's common stock during the same period.
http://finance.yahoo.com/marketupdate/inplay#mshl
DEVELOPMENTS:
CHART:
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
